Iferanserin

Iferanserin
Clinical data
ATC code	none;
Identifiers
	IUPAC name (E)-N-[2-[2-[(2S)-1-methylpiperidin-2-yl]ethyl]phenyl]-3-phenylprop-2-enamide;
CAS Number	58754-46-4 ;
PubChem CID	6445539;
ChemSpider	4949235;
UNII	NWR3BEB8PA;
ChEMBL	ChEMBL2107754;
Chemical and physical data
Formula	C23H28N2O
Molar mass	348.490 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(\C=C\c1ccccc1)Nc2ccccc2CC[C@H]3N(C)CCCC3;
	InChI InChI=1S/C23H28N2O/c1-25-18-8-7-12-21(25)16-15-20-11-5-6-13-22(20)24-23(26)17-14-19-9-3-2-4-10-19/h2-6,9-11,13-14,17,21H,7-8,12,15-16,18H2,1H3,(H,24,26)/b17-14+/t21-/m0/s1; Key:UXIPFQUBOVWAQW-UEBLJOKOSA-N;

Iferanserin (INN; VEN-309) is a drug which acts as a selective 5-HT_2A receptor antagonist.[1] It is under development as an intra-rectal formulation for the treatment of hemorrhoid disease, and as of February 2012, is in phase IIb clinical trials.[1]

References

Herold A, Dietrich J, Aitchison R (February 2012). "Intra-anal Iferanserin 10 mg BID for hemorrhoid disease: a prospective, randomized, double-blind, placebo-controlled trial". Clinical Therapeutics. 34 (2): 329–40. doi:10.1016/j.clinthera.2011.12.012. PMID 22244049.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.